 <h1>Atorvastatin / ezetimibe Side Effects</h1><ul class="nav-tabs nav-tabs-collapse nav-tabs-pill">
<li>Overview</li>
<li><b class="nav-item here">Side Effects</b></li>
<li>Dosage</li>
<li>Interactions</li>
<li>Pregnancy</li>
<li class="nav-more">
More&lt;svg aria-hidden="true" class="ddc-icon ddc-icon-down" focusable="false" height="16" viewbox="0 0 24 24" width="16" xmlns="http://www.w3.org/2000/svg"&gt;&lt;path d="M18.5 7.94L19.56 9 12 16.56 4.44 9 5.5 7.94l6.5 6.5z"&gt;&lt;/path&gt;&lt;/svg&gt;
</li>
</ul><ul>
<li>Managing Side Effects</li>
</ul><p><i>Applies to atorvastatin/ezetimibe: oral tablet</i></p><h3>General</h3><p>The more commonly reported adverse reactions have included increased ALT, increased AST, and musculoskeletal pain.<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Common</b> (1% to 10%): ALT increased (5%), AST increased (4%)</p><p><b>Postmarketing reports</b>: Hepatitis, cholelithiasis, cholecystitis, fatal and nonfatal hepatic failure<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Musculoskeletal pain (3.8 to 4%), arthralgia (3 to 6.9%), pain in extremity (2.7 to 6%), myalgia (3.5%), muscle spasms (3%), muscle weakness (2%)</p><p><b>Postmarketing reports</b>: Myopathy/rhabdomyolysis, necrotizing myopathy (rarely), injury, poisoning and procedural complication, tendon rupture, myositis<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Common</b> (1% to 10%): Diarrhea (4.1 to 6.8%), abdominal pain (3%), nausea (3 to 4%), dyspepsia (4.7%)<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Dizziness (2 to 6%), insomnia (3%), fatigue (2.4%)</p><p><b>Postmarketing reports</b>: Headache, paraesthesia, peripheral neuropathy, amnesia, memory impairment, confusion, depression, dizziness<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Common</b> (1% to 10%): Hyperkalemia (2%)<sup>[Ref]</sup></p><h3>Endocrine</h3><p><b>Common</b> (1% to 10%): Hot flushes (2%)<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Urinary tract infection (5.7%)<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Postmarketing reports</b>: Thrombocytopenia, elevated creatine phosphokinase<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Postmarketing reports</b>: Anaphylaxis, hypersensitivity reactions<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Common</b> (1% to 10%): Influenza (2%)<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Coughing (2 to 3%), bronchitis (2%), sinusitis (2 to 2.8%), upper respiratory tract infection (4.3%), nasopharyngitis (up to 8.3%), pharyngolaryngeal pain (up to 2.3%)</p><p><b>Postmarketing reports</b>: Interstitial lung disease<sup>[Ref]</sup></p><h3>Other</h3><p><b>Postmarketing reports</b>: Fatigue</p><h3>Dermatologic</h3><p><b>Postmarketing reports</b>: Angioedema, bullous rashes (including erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis), rash, urticaria<sup>[Ref]</sup></p><p id="ref_1">1. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_2">2. "Product Information. Liptruzet (atorvastatin-ezetimibe)." Merck &amp; Company Inc, Whitehouse Station, NJ. </p><h2>More about atorvastatin / ezetimibe</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Drug class: antihyperlipidemic combinations</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Advanced Reading</li>
</ul><h3>Professional resources</h3><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>High Cholesterol</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>